Parabilis Medicines (NASDAQ:PBLS) Upgraded at Lifesci Capital

Parabilis Medicines (NASDAQ:PBLS) was upgraded by analysts at Lifesci Capital to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

A number of other equities research analysts have also recently weighed in on PBLS. Evercore assumed coverage on Parabilis Medicines in a research note on Monday. They issued an “outperform” rating on the stock. Guggenheim assumed coverage on shares of Parabilis Medicines in a research report on Monday. They set a “buy” rating and a $40.00 price objective for the company. Leerink Partners initiated coverage on shares of Parabilis Medicines in a report on Monday. They issued an “outperform” rating and a $40.00 price objective on the stock. Wall Street Zen upgraded shares of Parabilis Medicines to a “hold” rating in a report on Saturday, June 20th. Finally, Bank of America started coverage on shares of Parabilis Medicines in a report on Monday. They set a “buy” rating and a $45.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $41.67.

Parabilis Medicines Stock Up 1.0%

Shares of PBLS traded up $0.29 during mid-day trading on Monday, reaching $29.49. The company’s stock had a trading volume of 109,248 shares, compared to its average volume of 939,208. Parabilis Medicines has a 1-year low of $24.51 and a 1-year high of $34.47.

Insider Transactions at Parabilis Medicines

In other Parabilis Medicines news, Director Alan Sebulsky bought 12,500 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the transaction, the director directly owned 12,500 shares in the company, valued at approximately $250,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Guy Levy bought 500,000 shares of the stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $20.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the insider directly owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. This trade represents a 94.88% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have purchased 530,000 shares of company stock worth $10,723,528.